APO-CANDESARTAN TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
29-01-2019
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
CANDESARTAN CILEXETIL
から入手可能:
APOTEX INC
ATCコード:
C09CA06
INN（国際名）:
CANDESARTAN
投薬量:
16MG
医薬品形態:
TABLET
構図:
CANDESARTAN CILEXETIL 16MG
投与経路:
ORAL
パッケージ内のユニット:
100/500
処方タイプ:
Prescription
治療領域:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
製品概要:
Active ingredient group (AIG) number: 0135220003; AHFS:
認証ステータス:
APPROVED
承認日:
2012-12-20
製品の特徴
_APO-CANDESARTAN Tablets Product Monograph_
Page 1 of 34
PRODUCT MONOGRAPH
PR
APO-CANDESARTAN
CANDESARTAN CILEXETIL TABLETS USP
4 MG, 8 MG, 16 MG AND 32 MG
ANGIOTENSIN II AT
1 RECEPTOR BLOCKER
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
JANUARY 29, 2019
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER: 222632
_APO-CANDESARTAN Tablets Product Monograph_
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 3
_SUMMARY PRODUCT INFORMATION
.................................................................................................
3_
_INDICATIONS AND CLINICAL USE
.......................................................................................................
3_
_CONTRAINDICATIONS
...........................................................................................................................
3_
_WARNINGS AND
PRECAUTIONS..........................................................................................................
4_
_ADVERSE REACTIONS
..........................................................................................................................
7_
_DRUG INTERACTIONS
.........................................................................................................................
13_
_DOSAGE AND ADMINISTRATION
.......................................................................................................
16_
_OVERDOSAGE
.....................................................................................................................................
18_
_ACTION AND CLINICAL PHARMACOLOGY
........................................................................................
18_
_STORAGE AND STABILITY
..................................................................................................................
21_
_DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................................
21_
PART II: SCIENTIFIC INFORMATION
..................
完全なドキュメントを読む
